Feature | November 20, 2012

Societies Issue First Comprehensive Consensus Statement on Troponin Testing

Full clinical situation should be considered when ordering, interpreting test

November 20, 2012 — The American College of Cardiology (ACC), in collaboration with several other professional societies, has released the first comprehensive consensus document outlining clinical considerations for ordering and interpreting tests for troponin, a protein that indicates injury to the heart muscle.

Measuring troponin has been a valuable means to help evaluate patients with suspected heart attack (myocardial infarction) for nearly two decades. Although a positive troponin test is an accurate indicator of injury to the heart muscle, it is not specific to heart attack and may be a red flag for other illnesses or problems.

“We need to be thinking about why we are ordering the troponin test before we order it,” said Kristin Newby, M.D., MHS, of Duke University Medical Center and co-chair of the writing committee for the ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations. “We hope this document provides a road map to help clinicians be more deliberate when ordering these tests and interpreting the results.”

Troponin helps the heart muscle contract. When the heart muscle is damaged by a heart attack or other illness, the cells die and release troponin into the bloodstream. Troponin levels can remain high for one to two weeks after a heart attack, making it especially useful along with an electrocardiogram (ECG/EKG) and other cardiac biomarkers such as CK-MB.

Even though an elevated troponin level signifies damage to the heart muscle, it does not in and of itself tell clinicians what might have caused the injury. Since troponin testing was first introduced in the early 1990s, it has predominantly been used and defined in the context of diagnosing or ruling out heart attack; but heart failure, surgery, trauma, kidney disease and pulmonary embolism are among other conditions that can lead to elevated troponin levels.

“There are many things that can cause damage to the heart muscle that would allow troponin to leak in the circulation where we can measure it, and it’s not always due to heart attack,” Newby said. “So if we are indiscriminate in how we order these tests or we aren’t paying attention to the clinical scenario before us, we may miss something important.”

Another key point emphasized in the report is that regardless of why someone has a positive troponin result, it is highly associated with worse outcomes and, therefore, needs to be looked into further.

“If you have a pulmonary embolism or end-stage renal disease and your troponin is elevated, your prognosis – how you are expected to do – is worse,” said Newby. “Just as if you have a heart attack and your troponin is positive, your prognosis is likely worse than in someone with unstable angina whose troponin [level] is not elevated.”

In this way, elevated troponin levels can also be used to help guide treatment and gauge patient appropriateness for more aggressive therapy. “It is incumbent on all practitioners to fully understand the implications of an elevated troponin level in a given patient in order to initiate the appropriate treatment and to optimize outcomes,” the document states.

Still, Newby cautions that troponin levels should not be used in isolation or as a routine screening test in the emergency department or other settings. “It’s a great marker, it does exactly what it is supposed to do, but how we interpret the results has to consider the clinical context in which the test was ordered,” said Newby, adding that careful attention will allow for optimal interpretation, diagnosis, risk stratification and patient management.

In addition to providing a review of the most recent research on troponin testing and its clinical applications, the document also provides useful at-a-glance resources including:

  • Frequently asked questions regarding the use of troponin in the clinical setting – what an elevated troponin level means, when the test should be ordered and prognosis;
  • A schematic of potential reasons for elevated troponin levels; and
  • Flow diagrams to help clinicians determine when to use troponin in therapeutic decision-making.


This document was developed in collaboration with the American Association for Clinical Chemistry, American College of Chest Physicians, American College of Emergency Physicians, American Heart Association (AHA), and Society for Cardiovascular Angiography and Interventions (SCAI). The writing committee represents a broad spectrum of clinicians who typically use troponin testing, including those from emergency and family medicine to cardiologists. As troponin tests become more sensitive, experts say conditions that result in smaller spikes in troponin will be identified.

The full report will be published in the Dec. 12, 2012, issue of the Journal of the American College of Cardiology and will be accessible on the ACC website.

For more information: www.cardiosource.org/acc

Related Content

LindaCare, expansion, remote patient monitoring, CIEDs, cardiac implantable electronic devices, United States
News | Remote Monitoring| January 18, 2017
LindaCare announced that it will open a new customer support facility in Connecticut to support growing interest in...
stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Cardiac Diagnostics| January 18, 2017
A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS) investigators...
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Suntech Medical, Oscar 2 ambulatory blood pressure monitoring system, ABPM, Patient Diary App, SphygmoCor Inside
Technology | Blood Pressure Monitor| January 17, 2017
The new SunTech Oscar 2 24-hour ambulatory blood pressure monitoring system is now available with the True24 ABPM...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
Overlay Init